CFDA Granted Approval of Phase I to III Clinical Trials for XZP-3287,a Category 1.1 Innovative Drug
CFDA Granted Approval of Phase II/III Clinical Trials for Imigliptin Hydrochloride,a category 1.1 antidiabetic drug
The injectable antibiotic Benapenem, National Category 1.1 new drug, is tested on human for the first time. It is well tolerated in subjects;Covance and XuanZhu Pharma announce partnership for preclinical and clinical portfolio development;FPI is achieved in the US for Pirotinib, National Category 1.1 anti-cancer new drug;The IND of national Category 1.1 anti-oncology new drug Sirotinib is approved by CFDA;CFDA granted IND applications to Pirotinib Hydrochloride, a category 1.1 anti-oncology drug.